Research institute
Appears in 1 story
Co-developer of Mprosevir
China's drug regulator granted conditional approval to Mprosevir, a COVID-19 treatment, on September 2. It is the country's first 'Class 1' innovative drug developed with AI assistance—the highest classification in China's drug registration system, reserved for drugs never marketed domestically or abroad.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
